ClinicalTrials.gg
RecruitingNCT06845371Updated May 4, 2026

MELODY Registry Follow-Up Study

An observational study in Congenital Heart Disease (CHD), sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University Hospital Tuebingen · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
845
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Heart Defects, Congenital with a site in Germany — 15 open to participants now, 15 under way, none of them phase 3. Heart Defects, Congenital · Germany.

Planned enrollment
3rd of 14
845 · median 300
Started
2026
with 3 others
Observational
14 of 38
8 open now
Primary completion
2027-05
later than 4 of 14 live
Registered
31st of 38
by date

Among the 38 studies in Heart Defects, Congenital with a site in Germany, this one is the 3rd largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2026, is one of 14 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 31st registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

15 of the 38 studies in Heart Defects, Congenital with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Heart Defects, Congenital with a site in Germany, or all of them as a file.
02

Study summary

Extension of the MELODY Registry, to assess longterm follow-up clinical results of Melody valve implantation after its commercialization in Europe / OUS

03

Conditions studied

  • Congenital Heart Disease (CHD)
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who underwent Melody valve implantation into the pulmonary position after its commercialization in Europe / OUS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • previous inclusion in the MELODY Registry

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
845 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. primary outcome

    • composite endpoint of TPVI related follow-up events (i.e. death, reoperation, or reintervention \>48h after TPVI)

    Time frame: from december 2006 up to December 2027

Secondary outcomes

  1. secondary measure

    TPVI infective endocarditis (I.E.) according to modified Duke criteria n

    Time frame: from december 2006 up to December 2027

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2025
First posted
Feb 25, 2025
StartActual
Apr 1, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
Aug 1, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06845371
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Apr 1, 2026
Primary completion
May 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
May 4, 2026

Study contacts

Johannes Nordmeyer, Prof
Contact
Johannes.Nordmeyer@med.uni-tuebingen.de
+49 (0) 7071 29-84751

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion